Vijay Kumar Panthi | Medicine and Health Sciences | Best Researcher Award

Published on by Popular Engineer

Mr. Vijay Kumar Panthi | Medicine and Health Sciences | Best Researcher Award

PhD Candidate, Queensland University of Technology, Australia

Vijay Kumar Panthi is a seasoned professional in Pharmaceutics with a focus on drug delivery and formulation. He holds a Master’s degree in Pharmacy (Pharmaceutics) from Mokpo National University, South Korea, and a Bachelor’s degree in Pharmacy from Tribhuvan University, Nepal. With extensive experience in formulation, research, and development, he has worked with several prominent pharmaceutical companies, including Royal Sasa Nepal Pharmaceuticals and Corel Pharmaceuticals. His expertise spans across nanoformulations, drug delivery systems, and formulation development for anticancer and anti-aging treatments. He has also contributed to several publications and conference posters, particularly in the field of nanomedicine, wound healing, and oral drug bioavailability. His research interests center around enhancing drug solubility and permeability, particularly for anticancer and diabetes treatments. He is a registered pharmacist with the Pharmacy Council of Nepal and actively engages in clinical pharmacy training and regulatory affairs.

Profile

Education

Vijay Kumar Panthi completed his Master’s in Pharmacy (Pharmaceutics) from Mokpo National University, South Korea, between 2017-2019. This advanced program deepened his knowledge of drug formulation, nanoformulations, and drug delivery systems. He earned his Bachelor’s degree in Pharmacy from Tribhuvan University, Nepal, at Sunsari Technical College, Dharan, between 2010 and 2014. Additionally, he completed Intermediate studies in Pharmacy at the Nepal Institute of Medical Science and Technology (NIMST), Kathmandu. Before that, he graduated from Mukti Higher Secondary School, Pyuthan, Nepal, in 2005. His academic journey has provided him with a solid foundation in pharmaceutical sciences and research, focusing on developing innovative solutions to improve drug efficacy and bioavailability, particularly in cancer and diabetes therapies.

Experience

Vijay Kumar Panthi has over 10 years of experience in the pharmaceutical industry, spanning formulation development, research, and regulatory affairs. He currently serves as the Manager of Formulation, Research, and Development (FR&D) at Royal Sasa Nepal Pharmaceuticals. Prior to this, he held the same position at Corel Pharmaceuticals Pvt. Ltd., where he developed and tested various drug formulations. His experience also includes conducting formulation and development research at Mokpo National University, South Korea, between 2017 and 2019. Additionally, he worked at Asian Pharmaceuticals Pvt. Ltd., where he contributed to GMP-certified projects, regulatory affairs, and validation processes. He has also participated in industrial training at companies like Everest Pharmaceuticals, Nepal, and Zydus Healthcare, India, which further honed his practical knowledge. Vijay’s diverse experience across multiple pharmaceutical functions highlights his expertise in drug formulation and development, particularly for anticancer and anti-aging applications.

Research Focus

Vijay Kumar Panthi’s primary research interests lie in the formulation of drug delivery systems, particularly for anticancer and diabetes treatments. His work focuses on enhancing the solubility, permeability, and bioavailability of active pharmaceutical ingredients (APIs), particularly those with limited oral bioavailability. In his Master’s thesis, he worked on the co-delivery system of pemetrexed and quercetin via multiple nanoemulsions to improve oral bioavailability and anticancer efficacy. His interest in nanoformulations extends to other therapeutic areas such as wound healing and anti-aging. By utilizing nanoemulsions, liposomes, and hydrogels, Vijay aims to develop novel drug delivery systems that improve the therapeutic outcomes of drugs for various diseases, especially chronic conditions like cancer and diabetes. His research on the formulation of anti-acne treatments and serine protease formulations for inflammation also demonstrates his versatility and commitment to improving patient care through scientific advancements.

Publication Top Notes

  1. Characterization and In Vivo Evaluation of an Oral Multiple Nanoemulsive System for Co-Delivery of Pemetrexed and Quercetin 📚💊
  2. Preparation, Characterization, and Biological Activities of Topical Anti-Aging Ingredients in a Citrus junos Callus Extract 🍊💆‍♂️
  3. Formulation and Development of Adapalene Topical Nanohydrogel Using Different Surfactants and Cosurfactants for Antiacne Activity: In Vitro and Ex Vivo Evaluation 🧴🔬
  4. Enhanced Oral Absorption of Pemetrexed by Ion-Pairing Complex Formation with Deoxycholic Acid Derivative and Multiple Nanoemulsion Formulations 💊🧪
  5. Formulation and Development of Serratiopeptidase Enteric Coated Tablets and Analytical Method Validation by UV Spectroscopy 🧫🔬
  6. A Validated RP-HPLC Method for Simultaneous Determination of Cefixime and Clavulanic Acid Powder in Pediatric Oral Suspension 🧪👶
  7. Preparation and Characterization of Callus Extract From Pyrus pyrifolia and Investigation of Its Effects on Skin Regeneration 🍐🧴
  8. Formulation and Development of Water-in-Oil Emulsion-Based Luliconazole Cream: In Vitro Characterization and Analytical Method Validation by RP-HPLC 🧴🔬

 

 

Jorge Amador Berlanga-Acosta | Medicine and Health Sciences | Best Researcher Award

Published on by Popular EngineerLeave a Comment on Jorge Amador Berlanga-Acosta | Medicine and Health Sciences | Best Researcher Award

Prof Dr Jorge Amador Berlanga-Acosta | Medicine and Health Sciences | Best Researcher Award

Research project leader, Center for Genetic Engineering and Biotechnology, Cuba

Dr. Jorge Amador Berlanga Acosta is a distinguished Cuban veterinary medicine and pharmaceutical scientist, born on October 11, 1962, in Bayamo, Granma, Cuba. With a career spanning over three decades, he specializes in the pharmacological applications of Epidermal Growth Factor (EGF) for wound healing and diabetic foot ulcers. He holds several prestigious titles, including Member of Honor of the Cuban National Academy of Science and Distinguished Professor at the University of Electronic Science and Technology of China. Dr. Berlanga has made significant contributions to biomedical research and has been instrumental in various clinical trials and technical missions across multiple continents, earning recognition for his impactful work in regenerative medicine and pharmacology. His expertise is complemented by a strong commitment to education and mentorship in the scientific community. 🌟

Profile

Google Scholar

Strengths for the Award

  1. Extensive Education and Training: Dr. Berlanga has a solid academic background with a Doctor of Veterinary Medicine and a Ph.D. in Pharmaceutical Sciences and Pharmacology. His post-doctoral fellowships at prestigious institutions like the University of Alberta and Imperial Cancer Research Fund highlight his commitment to advancing medical knowledge.
  2. Research Contributions: His extensive work on epidermal growth factor (EGF) and its applications in wound healing, particularly in diabetic foot ulcers, is groundbreaking. He has led numerous research projects and has a substantial number of publications in reputable journals, indicating his active engagement in critical biomedical research.
  3. Recognition and Awards: Dr. Berlanga has received numerous prestigious awards, including the “Héroe del Trabajo de la República de Cuba” and various international recognitions, showcasing his impact and contributions to the field.
  4. Leadership in Scientific Community: His roles in coordinating research commissions, leading projects, and serving as a speaker at over 40 international conferences illustrate his leadership and influence in the scientific community.
  5. Multidisciplinary Approach: His research spans various aspects of pharmacology, tissue repair, and regenerative medicine, demonstrating his ability to integrate knowledge across disciplines effectively.
  6. International Collaboration: Dr. Berlanga’s involvement in international workshops and conferences shows his commitment to collaboration and the dissemination of knowledge globally.

Areas for Improvement

  1. Broader Research Scope: While Dr. Berlanga’s focus on EGF is significant, exploring additional areas of research could enhance his impact. Diversifying his research portfolio may lead to novel insights and applications in other fields of medicine.
  2. Public Engagement and Communication: Increasing his outreach efforts to communicate research findings to the general public could enhance the visibility of his work and its implications for healthcare.
  3. Mentorship Opportunities: Engaging more with younger researchers and students through mentorship programs could foster the next generation of scientists and broaden the research community’s perspectives.
  4. Interdisciplinary Collaboration: Further collaboration with other scientific disciplines, such as engineering or technology, could lead to innovative approaches in his research areas.

Education

Dr. Berlanga’s educational journey began with primary education in Bayamo, Granma, followed by secondary schooling. He obtained his Doctor of Veterinary Medicine from the Universidad de Granma in 1985. He furthered his studies with a PhD in Pharmaceutical Sciences and Pharmacology from the Universidad de La Habana in 2000. His academic pursuits included post-doctoral fellowships at renowned institutions, such as the University of Alberta in Canada and the Leicester General Hospital in the UK, focusing on wound healing and gastroenterology. Additionally, he completed numerous specialization courses in clinical pathology, molecular biology, and experimental pharmacology. His diverse educational background has equipped him with the knowledge and skills to advance biomedical research and contribute to the field significantly. 🎓

Experience

Dr. Berlanga’s professional experience includes roles as an instructor and assistant lecturer in Anatomical Pathology at the Universidad de Granma and as an Associate Professor of Pathology. He has been a researcher at the Centro de Ingeniería Genética y Biotecnología (CIGB) in Havana, focusing on EGF’s pharmacological effects and wound healing mechanisms. Over the years, he has led various departments and projects within CIGB, including preclinical studies and diabetic foot ulcer healing initiatives. His leadership has driven significant advancements in understanding tissue repair and regeneration. In addition to his research, Dr. Berlanga has been a prominent speaker at numerous international conferences, sharing his findings and fostering collaboration in the scientific community. His extensive experience has established him as a leading figure in the field of biomedical sciences. 🔬

Awards and Honors

Dr. Berlanga’s contributions to science have earned him numerous accolades. He received the Alberta Heritage Foundation Scholarship in 1995 and the Royal Society Annual Award in 1998. In 2011, he was honored with the Distinción Carlos J. Finlay and recognized by the World Intellectual Property Organization as the best young inventor. His achievements include being named Hijo Ilustre de Granma and Bayamo, as well as receiving the prestigious title of Héroe del Trabajo de la República de Cuba in 2020. He has also been acknowledged as a Distinguished Professor at the University of Electronic Science and Technology of China. These awards highlight his significant impact on science and society through innovative research and dedication to education. 🏆

Research Focus

Dr. Berlanga’s research primarily focuses on the pharmacological applications of Epidermal Growth Factor (EGF) in wound healing and tissue regeneration. His investigations have led to the development of various animal models to study EGF’s effects on diabetic foot ulcers, ischemia/reperfusion injury, and gastrointestinal health. He explores the molecular mechanisms underlying EGF’s protective properties and its role in enhancing healing processes. His work also includes studying cellular pathologic memory and its implications in diabetes and wound chronicity. Dr. Berlanga’s commitment to advancing regenerative medicine continues to shape therapeutic strategies for complex wound healing challenges, making significant contributions to biomedical science. 🧬

Publication Top Notes

  • Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis
  • The pro‐inflammatory environment in recalcitrant diabetic foot wounds
  • Intra‐lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo …
  • Epidermal growth factor in clinical practice–a review of its biological actions, clinical indications and safety implications
  • Intralesional administration of epidermal growth factor‐based formulation (Heberprot‐P) in chronic diabetic foot ulcer: treatment up to complete wound closure
  • Intralesional injections of Citoprot‐P® (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation
  • Glucose toxic effects on granulation tissue productive cells: the diabetics’ impaired healing
  • Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds
  • Diabetic foot ulcers and epidermal growth factor: revisiting the local delivery route for a successful outcome
  • Gastrointestinal cell proliferation and crypt fission are separate but complementary means of increasing tissue mass following infusion of epidermal growth factor in rats
  • Diabetic lower extremity wounds: the rationale for growth factors‐based infiltration treatment
  • Healing enhancement of diabetic wounds by locally infiltrated epidermal growth factor is associated with systemic oxidative stress reduction
  • Cellular senescence as the pathogenic hub of diabetes-related wound chronicity
  • Wound chronicity, impaired immunity and infection in diabetic patients
  • Insulin resistance at the crossroad of Alzheimer disease pathology: A review
  • Potency and stability of C terminal truncated human epidermal growth factor
  • Systemic translation of locally infiltrated epidermal growth factor in diabetic lower extremity wounds
  • Epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) as tissue healing agents: clarifying concerns about their possible role in malignant transformation and …
  • Intestinal growth in parenterally‐fed rats induced by the combined effects of glucagon‐like peptide 2 and epidermal growth factor
  • Medical practice confirms clinical trial results of the use of intralesional human recombinant epidermal growth factor in advanced diabetic foot ulcers

Conclusion

Dr. Jorge Amador Berlanga Acosta exemplifies the qualities of an outstanding researcher through his extensive educational background, significant contributions to science, and recognized leadership. His innovative work on EGF and wound healing positions him as a strong candidate for the Best Researcher Award. By broadening his research scope, enhancing public engagement, and fostering mentorship, he can further elevate his impact on the scientific community and society at large.